AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30601407 — intervention group
Group type: COMPARATOR
Intervention: Circulating microparticles from age-matched control subjects
Number of subjects: 100
Study 30601407 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating microparticles from patients with VHD before surgery
Number of subjects: 100
Study 30601407 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating microparticles from patients with VHD after surgery
Number of subjects: 100
Study 28390289 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib 24 mg orally once daily
Number of subjects: 10
Study 26939323 — intervention group
Group type: EXPERIMENTAL
Intervention: Huolong moxibustion, applied once a day for 3 weeks
Number of subjects: 65
Study 26939323 — intervention group
Group type: COMPARATOR
Intervention: Routine traction combined with massage therapy, applied once a day for 3 weeks
Number of subjects: 65
Study 23735418 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum magnesium (sMg) levels (<2.0 mg/dL)
Number of subjects: 0
Study 23735418 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intracellular magnesium (iMg) levels (<3.75 mg/dL erythrocytes)
Number of subjects: 0
Study 21255610 — intervention group
Group type: EXPERIMENTAL
Intervention: NIM811 monotherapy (doses of 10 to 600 mg orally once or twice daily)
Number of subjects: 12
Study 21255610 — intervention group
Group type: EXPERIMENTAL
Intervention: NIM811 (600 mg bid) in combination with pegylated interferon alpha (PEG‐IFN‐α)
Number of subjects: 12
Study 21255610 — intervention group
Group type: COMPARATOR
Intervention: PEG‐IFN alone
Number of subjects: 12
Study 19317999 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective internal radioembolization (SIR) for patients without venous thrombosis (20 patients)
Number of subjects: 52
Study 19317999 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective internal radioembolization (SIR) for patients with venous thrombosis (15 patients)
Number of subjects: 52
Study 19317999 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care for untreated patients (17 patients, 10 with VT)
Number of subjects: 52
Study 19317999 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including treated and untreated)
Number of subjects: 52
Study 16816014 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 120
Study 15163494 — intervention group
Group type: EXPERIMENTAL
Intervention: High throughput RT-PCR (HTP RT-PCR)
Number of subjects: 4176
Study 15163494 — intervention group
Group type: COMPARATOR
Intervention: Culture confirmation
Number of subjects: 4176
Study 10961521 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-electrolyte solution (CE)
Number of subjects: 9
Study 10961521 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 9
Study 9278966 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral condition (subject alone makes the decision)
Number of subjects: 0
Study 9278966 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilateral condition (everyone participates in reward allocation)
Number of subjects: 0
Study 9278966 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 0
Study 8173195 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human E coli derived granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) at 250 micrograms/m2
Number of subjects: 14
Study 8173195 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human E coli derived granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) at 500 micrograms/m2
Number of subjects: 14
Study 8173195 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human E coli derived granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) at 750 micrograms/m2
Number of subjects: 14
Study 8173195 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human E coli derived granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) at 1,000 micrograms/m2
Number of subjects: 14
Study 8173195 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human E coli derived granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) at all dose levels
Number of subjects: 14
Study 8173195 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human E coli derived granulocyte‐macrophage colony‐stimulating factor (GM‐CSF)
Number of subjects: 14
Study 2868736 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental loading added to standard therapy
Number of subjects: 262
Study 2868736 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 262
Study 30575560 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg daily for 4 weeks
Number of subjects: 30
Study 30575560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 27224908 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol ER (25-250 mg)
Number of subjects: 182
Study 27224908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 24476454 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropicamide 1%
Number of subjects: 90
Study 24476454 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 2.5%
Number of subjects: 90
Study 24476454 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears (Control)
Number of subjects: 90
Study 23600541 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous for variant alleles of ALOX5 promoter SP1 tandem repeat (rs59439148)
Number of subjects: 270
Study 23600541 — intervention group
Group type: COMPARATOR
Intervention: All children
Number of subjects: 270
Study 20197167 — intervention group
Group type: EXPERIMENTAL
Intervention: Bite wafer (BW)
Number of subjects: 0
Study 20197167 — intervention group
Group type: COMPARATOR
Intervention: Over-the-counter analgesics (OTC)
Number of subjects: 0
Study 18550582 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily free distribution program
Number of subjects: 12
Study 18550582 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent program (classroom curriculum and parental involvement)
Number of subjects: 12
Study 18550582 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 12
Study 16409336 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot needle anchoring during wide bore needle puncture (group 2)
Number of subjects: 157
Study 12242514 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO plus G‐CSF
Number of subjects: 361
Study 12242514 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO plus GM‐CSF
Number of subjects: 361
Study 9682041 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of alendronate per day
Number of subjects: 477
Study 9682041 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of alendronate per day
Number of subjects: 477
Study 9682041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 477
Study 9682041 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (both doses)
Number of subjects: 477
Study 7897120 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 695
Study 7897120 — intervention group
Group type: COMPARATOR
Intervention: No thrombolytic therapy (baseline ECG)
Number of subjects: 695
Study 2482549 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 10172 (750 anti-Xa units/day, 500 units bid, or 750 units bid)
Number of subjects: 48
Study 2482549 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subcutaneous injections)
Number of subjects: 48
Study 178852 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated respiratory syncytial virus ts‐1 vaccine administered intranasally at a low dose (100 TCID50)
Number of subjects: 25
Study 31703434 — intervention group
Group type: EXPERIMENTAL
Intervention: C12 (0.3 kcal/min)
Number of subjects: 16
Study 31703434 — intervention group
Group type: EXPERIMENTAL
Intervention: C12+Trp (0.4 kcal/min)
Number of subjects: 16
Study 31703434 — intervention group
Group type: EXPERIMENTAL
Intervention: Trp (0.1 kcal/min)
Number of subjects: 16
Study 31703434 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 16
Study 29957709 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (VSL#3)
Number of subjects: 100
Study 29957709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 26418779 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular mail + $1 bill
Number of subjects: 608
Study 26418779 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular mail + $5 bill
Number of subjects: 608
Study 26418779 — intervention group
Group type: COMPARATOR
Intervention: Emailed with a link to an online survey
Number of subjects: 608
Study 26418779 — intervention group
Group type: COMPARATOR
Intervention: Regular mail
Number of subjects: 608
Study 24703046 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructosamine above the 95th percentile
Number of subjects: 12306
Study 24703046 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycated albumin above the 95th percentile
Number of subjects: 12306
Study 24703046 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructosamine
Number of subjects: 12306
Study 24703046 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycated albumin
Number of subjects: 12306
Study 24703046 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 12306
Study 21988334 — intervention group
Group type: COMPARATOR
Intervention: Tolvaptan 30 mg with ketoconazole 200 mg once daily for 3 days
Number of subjects: 38
Study 21988334 — intervention group
Group type: COMPARATOR
Intervention: Tolvaptan 240 mg with rifampicin 600 mg once daily for 7 days
Number of subjects: 38
Study 19632972 — intervention group
Group type: EXPERIMENTAL
Intervention: Email communication with physicians
Number of subjects: 4059
Study 19632972 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic factors (African Americans, Hispanics, men)
Number of subjects: 4059
Study 19632972 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of physician's communication skills and enthusiasm
Number of subjects: 4059
Study 19632972 — intervention group
Group type: EXPERIMENTAL
Intervention: Email usage
Number of subjects: 4059
Study 19632972 — intervention group
Group type: EXPERIMENTAL
Intervention: Age factor
Number of subjects: 4059
Study 19632972 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician enthusiasm
Number of subjects: 4059
Study 17935234 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch
Number of subjects: 561
Study 17935234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 561
Study 17935234 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (doses ≤8 mg/24 h)
Number of subjects: 561
Study 17935234 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole (doses ≤12 mg/day)
Number of subjects: 561
Study 15897937 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse case management
Number of subjects: 335
Study 15897937 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 335
Study 12483368 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (500 mg on each day of chemotherapy)
Number of subjects: 40
Study 12483368 — intervention group
Group type: COMPARATOR
Intervention: No amifostine (control group)
Number of subjects: 40
Study 12483368 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine
Number of subjects: 40
Study 9616310 — intervention group
Group type: EXPERIMENTAL
Intervention: Antituberculous chemotherapy
Number of subjects: 130
Study 9616310 — intervention group
Group type: COMPARATOR
Intervention: Control (no antituberculous chemotherapy)
Number of subjects: 130
Study 8594015 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 12
Study 8594015 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study 2613389 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid paracetamol dosage form
Number of subjects: 12
Study 2613389 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid paracetamol dosage form (tablets)
Number of subjects: 12
Study 2613389 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid paracetamol dosage form (tablets) with meal enriched in dietary fiber
Number of subjects: 12
Study 2613389 — intervention group
Group type: COMPARATOR
Intervention: Liquid and solid paracetamol dosage forms
Number of subjects: 12
Study 870376 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleet's Phospho‐Soda enema
Number of subjects: 10
Study 870376 — intervention group
Group type: EXPERIMENTAL
Intervention: bisacodyl (Dulcolax), 10 mg, by enema or suppository
Number of subjects: 10
Study 870376 — intervention group
Group type: COMPARATOR
Intervention: oral mannitol to induce diarrhea
Number of subjects: 10
Study 870376 — intervention group
Group type: COMPARATOR
Intervention: isotonic saline enema
Number of subjects: 10
Study 870376 — intervention group
Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 10
Study 31196803 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid bolus (saline or albumin)
Number of subjects: 3141
Study 31196803 — intervention group
Group type: COMPARATOR
Intervention: No fluid bolus
Number of subjects: 3141
Study 28831951 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk protein concentrate (PRO, 4×20 g on exercise day and 20 g/d for the following 8 days)
Number of subjects: 11
Study 28831951 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk protein concentrate (PRO)
Number of subjects: 11
Study 28831951 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 11
Study 25948101 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasotraline 8 mg/day
Number of subjects: 0
Study 25948101 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasotraline 4 mg/day
Number of subjects: 0
Study 25948101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24494295 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS)
Number of subjects: 80
Study 24494295 — intervention group
Group type: COMPARATOR
Intervention: Anesthesia group (control)
Number of subjects: 80
Study 24494295 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAS
Number of subjects: 80
Study 24494295 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 21324520 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily beclomethasone (twice daily, 40 μg per puff)
Number of subjects: 843
Study 21324520 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (twice daily beclomethasone with beclomethasone plus albuterol as rescue)
Number of subjects: 843
Study 21324520 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue beclomethasone (twice daily placebo with beclomethasone plus albuterol as rescue)
Number of subjects: 843
Study 21324520 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily placebo with placebo plus albuterol as rescue)
Number of subjects: 843
Study 18573120 — intervention group
Group type: EXPERIMENTAL
Intervention: New protocol for postoperative calcium management with iPTH measurement at 4 hours postoperatively
Number of subjects: 50
Study 18573120 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard postoperative care)
Number of subjects: 50
Study 17580440 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (Quchi, Lieque, Yuji, Neiguan, Zusanli, Sanyinjiao, Taixi) once daily for 12 days
Number of subjects: 71
Study 17580440 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with anti-asthma drugs (Cromolyn sodium, Albuterol, fenoterol)
Number of subjects: 71
Study 17580440 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment for moderate and severe asthma
Number of subjects: 71
Study 17580440 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with anti-asthma drugs
Number of subjects: 71
Study 15458772 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavir (Cipla Ltd, India; 40 mg capsule)
Number of subjects: 24
Study 15458772 — intervention group
Group type: COMPARATOR
Intervention: Zerit (Bristol-Myers Squib, NJ, USA; 40 mg capsule)
Number of subjects: 24
Study 12575376 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuejie Jiawei Decoction No. I, one dose per day for 7 days, starting from the 2nd day after abortion
Number of subjects: 0
Study 12575376 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuejie Jiawei Decoction No. II, one dose per day for 5 days, starting from the 11th day after abortion
Number of subjects: 0
Study 12575376 — intervention group
Group type: COMPARATOR
Intervention: Control group, untreated
Number of subjects: 0
Study 9622044 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine plus neuroleptic (dosage of clonidine varied from 0.2 to 0.6 mg per day, neuroleptic averaged 34 mg per day of haloperidol equivalents)
Number of subjects: 12
Study 9622044 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus neuroleptic (neuroleptic averaged 34 mg per day of haloperidol equivalents)
Number of subjects: 12
Study 1769029 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous patch application (Group A)
Number of subjects: 24
Study 1769029 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent application with 4 hours intervals (Group B)
Number of subjects: 24
Study 1769029 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent application with 6 hours intervals (Group C)
Number of subjects: 24
Study 1769029 — intervention group
Group type: EXPERIMENTAL
Intervention: First dose of the nitroglycerin patch
Number of subjects: 24
Study 6123129 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.5 mg)
Number of subjects: 20
Study 6123129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31276674 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully-covered self-expanding metal stents (FCSEMSs)
Number of subjects: 119
Study 31276674 — intervention group
Group type: COMPARATOR
Intervention: Uncovered self-expanding metal stents (UCSEMSs)
Number of subjects: 119
Study 28093604 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% 5-fluorouracil (5-FU) pretreatment for 7 days, twice daily before daylight-mediated photodynamic therapy (PDT)
Number of subjects: 24
Study 28093604 — intervention group
Group type: COMPARATOR
Intervention: Daylight-mediated photodynamic therapy (PDT) alone
Number of subjects: 24
Study 28093604 — intervention group
Group type: COMPARATOR
Intervention: Both groups (5-FU + PDT and PDT alone)
Number of subjects: 24
Study 25490525 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based walking exercise (40 min/day, 3 days/week for 12 weeks)
Number of subjects: 116
Study 25490525 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 116
Study 24909093 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1656 + glucagon
Number of subjects: 8
Study 24909093 — intervention group
Group type: COMPARATOR
Intervention: AZD1656 alone
Number of subjects: 8
Study 22392326 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolls fortified with microencapsulated iron sulfate (4 mg iron each), offered once a day, five days a week for 24 weeks.
Number of subjects: 173
Study 22392326 — intervention group
Group type: COMPARATOR
Intervention: Rolls without fortification (control group).
Number of subjects: 173
Study 20662314 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone maleate sustained-release floating microspheres
Number of subjects: 0
Study 20662314 — intervention group
Group type: COMPARATOR
Intervention: Commercial tablets (control)
Number of subjects: 0
Study 18363603 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoiesis stimulating agents (ESA)
Number of subjects: 2498
Study 18363603 — intervention group
Group type: COMPARATOR
Intervention: Indeterminate evidence of harm from ESA
Number of subjects: 2498
Study 15750513 — intervention group
Group type: EXPERIMENTAL
Intervention: Contreet Foam dressing
Number of subjects: 27
Study 12676472 — intervention group
Group type: EXPERIMENTAL
Intervention: PGME vapour at 150 ppm
Number of subjects: 12
Study 12676472 — intervention group
Group type: COMPARATOR
Intervention: PGME vapour at 100 ppm
Number of subjects: 12
Study 12676472 — intervention group
Group type: COMPARATOR
Intervention: PGME vapour at 0 ppm
Number of subjects: 12
Study 10686660 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg orally daily for 10 days
Number of subjects: 9
Study 10686660 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 9
Study 10686660 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 9
Study 9374089 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 104
Study 9374089 — intervention group
Group type: COMPARATOR
Intervention: FAC (5-fluorouracil/doxorubicin/cyclophosphamide)
Number of subjects: 104
Study 1549650 — intervention group
Group type: EXPERIMENTAL
Intervention: d-fenfluramine (d-FF)
Number of subjects: 12
Study 1549650 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (d-amp)
Number of subjects: 12
Study 1549650 — intervention group
Group type: EXPERIMENTAL
Intervention: d-fenfluramine (d-FF) + d-amphetamine (d-amp)
Number of subjects: 12
Study 1549650 — intervention group
Group type: EXPERIMENTAL
Intervention: l-fenfluramine (l-FF) + d-amphetamine (d-amp)
Number of subjects: 12
Study 1549650 — intervention group
Group type: EXPERIMENTAL
Intervention: l-fenfluramine (l-FF)
Number of subjects: 12
Study 1549650 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (d-amp) + d-fenfluramine (d-FF)
Number of subjects: 12
Study 2862892 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 35
Study 2862892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 31615801 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH-FLOW nasal oxygenation
Number of subjects: 530
Study 31615801 — intervention group
Group type: COMPARATOR
Intervention: LOW-FLOW nasal oxygenation
Number of subjects: 530
Study 29197091 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy for PTSD (CT-PTSD)
Number of subjects: 0
Study 29197091 — intervention group
Group type: COMPARATOR
Intervention: Usual care (waitlist control)
Number of subjects: 0
Study 27575854 — intervention group
Group type: EXPERIMENTAL
Intervention: KLOX BioPhotonic System (LED blue light device with photo-converter chromophores), treated for 6 weeks (twice weekly)
Number of subjects: 0
Study 25391047 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 182